AbbVie (ABBV) Deferred Taxes (2019 - 2026)

AbbVie has disclosed Deferred Taxes across 8 years of filings, most recently posting $137.0 million for Q1 2026.

• In Q1 2026, Deferred Taxes rose 589.29% year-over-year to $137.0 million; the TTM figure through Mar 2026 stood at -$327.0 million (up 69.94% YoY), while the FY2025 annual figure was -$492.0 million, up 66.05% from the prior year.
• Deferred Taxes improved to $137.0 million in Q1 2026, from -$385.0 million in the prior quarter.
• Over the last five years, Deferred Taxes for ABBV reached as high as $193.0 million in Q3 2025 and fell as low as -$1.4 billion in Q4 2023.
• The 5-year median for Deferred Taxes is -$368.0 million (2023), against an average of -$389.6 million.
• Annual changes were most pronounced in 2022 — Deferred Taxes plunged 1726.47% — and 2026, when it soared 589.29%.
• A 5-year view of Deferred Taxes shows it stood at -$516.0 million in 2022, then slumped by 169.57% to -$1.4 billion in 2023, then jumped by 44.86% to -$767.0 million in 2024, then soared by 49.8% to -$385.0 million in 2025, then surged by 135.58% to $137.0 million in 2026.
• According to Business Quant data, Deferred Taxes over the past three periods registered $137.0 million, -$385.0 million, and $193.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.